ArticleWellcome open research2025
SV2A is expressed in synapse subpopulations in mouse and human brain: implications for PET radiotracer studies.
Article in Wellcome open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mapping the Synaptome in Neurodegeneration: Emerging Clinical Applications of SV2A PET Imaging.Molecular diagnosis & therapy · 2026Article
- Autoradiographic assessment of SynVesT-1 revealed changes in non-displaceable binding with demyelination and remyelination: implications for SV2A PET analysis.EJNMMI research · 2026Article
- High-resolution in utero SV2A PET imaging of the nonhuman primate brain using the NeuroEXPLORER.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Article
- Increased levels of GFAP and purinergic P2X7 receptor in Alzheimer's disease brain are associated with Aβ, tau pathologies and synaptic loss.Alzheimer's research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synapse pathology is a feature of most brain diseases and there is a pressing need to monitor the onset and progression of this pathology using brain imaging in living patients. A major step toward this goal has been the development of small-molecule radiotracers that bind to synaptic vesicle glycoprotein 2A (SV2A) for use in positron emission tomography (PET). Changes in SV2A radiotracer binding in PET are widely interpreted to report differences in the density of all synapses throughout brain region However, the expression of SV2A at single-synapse level across regions of adult mouse and human brain has not been comprehensively characterised. Here, We employed high-resolution synaptome mapping in adult mouse (n=7) and human (n=3) brain tissue. Synaptic proteins were labelled using fluorescent immunohistochemistry, imaged using confocal microscopy and quantified using image analysis tools. Brain-wide SV2A expression was assessed in presynaptic and postsynaptic terminals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.